Literature DB >> 29652946

[Impact of the Chilean Explicit Guaranties Health System (GES) on breast cancer treatment].

César Del Castillo Sm1, M Elena Cabrera C2, Lea Derio P3, Fancy Gaete V4, Gabriel Cavada Ch5.   

Abstract

Background Breast cancer is the most common malignant tumor in women in the world. In 2005, it was incorporated to the Explicit Guaranties Health System (GES) in Chile. Aim To describe the demographic and clinical characteristics of breast cancer patients and to determine the effect of incorporating these women to GES. Material and Methods Medical records of 5,119 women with breast cancer aged 59 ± 14 years, attended at six public hospitals between 2000 and 2010 were reviewed. Median follow up was 87 months (range 1-182). Mortality was assessed using death certificates obtained at the National Identification Registry. Results Sixty six percent of women were in stage I-II, 29% in stage III and 5% in stage IV. Surgery was performed in 4023/5119 cases (79%), adyuvant radiotherapy in 3627/4517 cases (80%), chemotherapy in 3,204/3,424 cases (94%) and hormone therapy in 1,695/2,375 cases (71%). Between 2000 and 2010, there was a significant increase in the proportion of cases in stage I, from 8% to 25%, (p < 0.01). Overall survival (OS) increased 1% per year, since the beginning of GES system (p = 0.024). Five year OS was 75.1%. The figures for Stage I, II, III and IV were 93, 84, 62 and 27% respectively (p < 0.01). Patients without lymph node involvement and who were not triple negative, had a significantly better OS. Conclusions There was a significant increase in stage I cases, and a 1% per year OS improvement after GES system started, compared with the previous period.

Entities:  

Mesh:

Year:  2017        PMID: 29652946     DOI: 10.4067/s0034-98872017001201507

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  2 in total

1.  Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data.

Authors:  Benjamín Walbaum; Francisco Acevedo; Lidia Medina; M Loreto Bravo; Tomas Merino; Mauricio Camus; Francisco Dominguez; Sebastián Mondaca; Héctor Galindo; Bruno Nervi; Carolina Ibañez; Jorge Madrid; Sabrina Muñiz; José Peña; Érica Koch; Marcelo Garrido; Mauricio P Pinto; César Sánchez
Journal:  Ecancermedicalscience       Date:  2021-02-01

2.  Contrast-enhanced mammography predicts pathological response after neoadjuvant chemotherapy in locally advanced breast cancer.

Authors:  Daniel Canteros; Benjamin Walbaum; Miguel Córdova-Delgado; Andrés Torrealba; Constanza Reyes; María Elena Navarro; Dravna Razmilic; Mauricio Camus; Francisco Dominguez; Orieta Navarrete; Mauricio P Pinto; Gonzalo Pizarro; Francisco Acevedo; César Sánchez
Journal:  Ecancermedicalscience       Date:  2022-05-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.